KR20200044307A - Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component - Google Patents
Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component Download PDFInfo
- Publication number
- KR20200044307A KR20200044307A KR1020180124870A KR20180124870A KR20200044307A KR 20200044307 A KR20200044307 A KR 20200044307A KR 1020180124870 A KR1020180124870 A KR 1020180124870A KR 20180124870 A KR20180124870 A KR 20180124870A KR 20200044307 A KR20200044307 A KR 20200044307A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- mixture
- obesity
- green tea
- celery
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 32
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 32
- 230000036232 cellulite Effects 0.000 title claims abstract description 32
- 230000003579 anti-obesity Effects 0.000 title claims abstract description 18
- 230000009467 reduction Effects 0.000 title claims abstract description 9
- 239000000419 plant extract Substances 0.000 title abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 161
- 240000007087 Apium graveolens Species 0.000 claims abstract description 38
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims abstract description 37
- 235000010591 Appio Nutrition 0.000 claims abstract description 37
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 37
- 229940094952 green tea extract Drugs 0.000 claims abstract description 37
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 36
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 36
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 36
- 241000332371 Abutilon x hybridum Species 0.000 claims abstract description 35
- 235000013376 functional food Nutrition 0.000 claims abstract description 16
- 230000036541 health Effects 0.000 claims abstract description 16
- 208000008589 Obesity Diseases 0.000 claims abstract description 14
- 239000003674 animal food additive Substances 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 14
- 235000020824 obesity Nutrition 0.000 claims abstract description 14
- 241000218645 Cedrus Species 0.000 claims description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 241000219095 Vitis Species 0.000 claims 6
- 240000006365 Vitis vinifera Species 0.000 abstract description 30
- 150000002632 lipids Chemical class 0.000 abstract description 5
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 244000022372 Diospyros lotus Species 0.000 abstract 2
- 235000003333 Diospyros lotus Nutrition 0.000 abstract 2
- 230000007935 neutral effect Effects 0.000 abstract 1
- 239000006071 cream Substances 0.000 description 15
- 210000001789 adipocyte Anatomy 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000003925 fat Substances 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- -1 foundation Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000378 calcium silicate Substances 0.000 description 3
- 229910052918 calcium silicate Inorganic materials 0.000 description 3
- 235000012241 calcium silicate Nutrition 0.000 description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000009815 adipogenic differentiation Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001273 butane Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010988 intraclass correlation coefficient Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 235000020748 rosemary extract Nutrition 0.000 description 2
- 229940092258 rosemary extract Drugs 0.000 description 2
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000002764 Apium graveolens Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000019730 animal feed additive Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000001387 apium graveolens Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 식물 추출물의 혼합물을 유효성분으로 함유하는 항비만 및 셀룰라이트 감소용 조성물에 관한 것이다. The present invention relates to a composition for reducing anti-obesity and cellulite containing a mixture of plant extracts as an active ingredient.
비만이란 신체에 지방조직이 과잉 축적된 상태로, 남은 열량이 지방으로 전환되어 인체 내 피하조직이나 복부 장간막에 축적됨으로 인하여 체중이 정상인의 표준체중보다 25% 이상 초과되거나 신체질량지수(body mass index, BMI)가 27 이상일 때를 말한다. Obesity is a condition in which fat tissue is excessively accumulated in the body, and the remaining calories are converted to fat and accumulate in the subcutaneous tissue or abdominal mesentery of the human body, so that the body weight exceeds 25% or more of the normal body weight or the body mass index. , BMI) is 27 or more.
비만은 유전적, 영양적, 환경적 및 사회적 요인 등 다양한 원인들이 관여하는 복잡한 증후군으로서, 현대 사회에서는 식생활 패턴의 서구화 및 운동 부족 등으로 인하여 비만인구가 증가하는 추세에 있다. 2007년 국민 영양건강조사에 따르면, 만 19세 이상의 비만 인구는 31.7%로 나타났는데, 이는 1998년에 조사된 26%에 비하여 5.7%나 증가한 것이다.Obesity is a complex syndrome involving various causes such as genetic, nutritional, environmental, and social factors. In modern society, obesity is on the rise due to westernization of dietary patterns and lack of exercise. According to the 2007 National Nutritional Health Survey, the obesity population aged 19 and over was 31.7%, an increase of 5.7% compared to the 26% surveyed in 1998.
비만은 마른 체형이 아름다운 것으로 간주되는 현대 사회에서 미용상으로 문제된다. 또한 혈중 지질 농도를 높여 동맥경화와 심장병을 발생시키고, 인슐린 저항성을 높여 당뇨, 생리불순, 암 등의 합병증을 유발하고 고지혈증, 고혈압, 관상동맥 및 뇌졸중 등의 만성성인병 질환의 원인이 된다.Obesity is a cosmetic problem in modern society where skinny skin is considered beautiful. In addition, it increases the lipid concentration in the blood, which causes arteriosclerosis and heart disease, and increases insulin resistance, causing complications such as diabetes, menstruation, and cancer, and is a cause of chronic diseases such as hyperlipidemia, hypertension, coronary artery, and stroke.
비만과 관련하여 파생되는 문제 중의 하나가 셀룰라이트(cellulite)이다. 셀룰라이트는 피부 섬유 조직의 가닥들이 피부와 심부의 조직층을 연결하여 지방을 함유한 세포가 포함된 구획을 형성하고 상기 지방을 함유한 세포가 크기가 커지면서 결과적으로 구획이 커져 피부가 울퉁불퉁하게 되는 현상이다. One of the problems derived from obesity is cellulite. Cellulite is a phenomenon in which the strands of the skin fiber tissue connect the skin and the tissue layer of the deep part to form a compartment containing fat-containing cells, and as the cells containing the fat become larger, the compartment becomes larger and the skin becomes bumpy. to be.
셀룰라이트는 여성에서 특히 빈번하게 발생한다. 셀룰라이트가 축적된 부위에는 임파 체계의 이상으로 임파액이 정체됨으로써 그 부위에 일종의 부종이 발생하여 살이 더욱 찐 것처럼 보이는 현상도 나타날 수 있다.Cellulite occurs particularly frequently in women. In areas where cellulite has accumulated, lymphatic stagnation due to abnormalities in the lymphatic system may cause some edema to occur in the area, which may also appear to be more fattened.
셀룰라이트 역시 미용상으로 문제될 뿐 아니라, 임파액의 정체로 인해 체내에 독성 물질이 누적되어 피부 세포를 손상시키고 영양섭취를 억제하여 피부의 노화 및 세포 괴사까지 유발할 수 있다.Cellulite is not only a cosmetic problem, but due to the stagnation of lymphatic fluid, toxic substances accumulate in the body, damaging skin cells and suppressing nutrition, which can lead to skin aging and cell necrosis.
한편, 비만을 치료하기 위하여 식사 조절 및 운동 요법이 권장되고 있지만, 이러한 방법을 통해서는 효과가 나타나기까지 시간과 노력이 많이 들기 때문에, 다양한 보조식품이나 약물이 개발되어 있다. 그러나 시판되고 있는 보조식품이나 약물들은 대부분 인공적으로 합성한 화학 물질로서 다양한 부작용이 보고되어 있어 사용에 심각한 제한이 있다. 예를 들어 대표적인 비만 치료제인 오를리스타트(Orlistat)는 위와 소장 내에서 지방 분해효소인 리파아제(lipase)의 활성을 저해하여 지방흡수를 떨어뜨리는 기전으로 작용하지만, 지방변(steatorrhea), 배변 실금 등의 부작용을 유발한다는 보고가 있다. 또 다른 비만 치료제인 시부트라민 염산염(sibutramine hydrochloride)의 경우에는 교감신경계의 세로토닌과 노르아드레날린 농도를 증가시켜, 두통, 구갈, 식욕부진, 불면, 변비 등의 부작용을 나타내어 국내에서 판매가 금지되었다. 이외에도 항비만 약제로 개발된 제품들 중 상당수가 심각한 부작용으로 인해 판매가 금지된 바 있다. 따라서 안전한 천연 유래 물질을 이용한 항비만제의 개발이 요구되고 있다. On the other hand, although diet control and exercise therapy are recommended to treat obesity, various supplementary foods or drugs have been developed because it takes a lot of time and effort to show effectiveness through these methods. However, most commercially available supplements or drugs are artificially synthesized chemicals, and various side effects have been reported, which limits their use. For example, Orlistat, a representative treatment for obesity, acts as a mechanism to decrease fat absorption by inhibiting the activity of the lipolytic enzyme lipase in the stomach and small intestine, but side effects such as steatorrhea and bowel incontinence There is a report that causes. Sibutramine hydrochloride, another anti-obesity treatment, was banned in Korea because it increased the concentrations of serotonin and noradrenaline in the sympathetic nervous system, causing side effects such as headache, cramping, loss of appetite, insomnia, and constipation. In addition, many of the products developed as anti-obesity drugs have been banned due to serious side effects. Therefore, development of an anti-obesity agent using a safe natural-derived material is required.
한편, 한국공개특허 제2017-0109881호에는 녹차 추출물을 함유하는 비만 치료제가 개시되어 있고, 한국등록특허 제1852032호에는 도라지를 유효성분으로 포함하는 고지혈증 예방 효능의 도라지 함유 음료 및 이의 제조방법이 개시되어 있지만, 본 발명의 식물 추출물의 혼합물, 더욱 상세하게는 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 항비만 및 셀룰라이트 감소용 조성물에 관해 개시된 바 없다. On the other hand, Korean Patent Publication No. 2017-0109881 discloses a treatment for obesity containing green tea extract, and Korean Registered Patent No. 1852032 discloses a bellflower-containing beverage having anti-hyperlipidemic effect including bellflower as an active ingredient and a method for manufacturing the same However, the mixture of the plant extract of the present invention, more specifically, bellflower extract, celery extract, green tea extract, cedar leaf extract, and grape cluster stem extract containing as an active ingredient in an anti-obesity and cellulite reduction composition No disclosure has been made.
본 발명은 상기와 같은 요구에 의해 도출된 것으로, 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 항비만용 조성물을 제공하고, 상기 조성물의 지방생성 억제효과 및 셀룰라이트 감소효과를 확인함으로써, 본 발명을 완성하였다. The present invention is derived by the above-mentioned needs, to provide a composition for anti-obesity containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract as an active ingredient, The present invention was completed by confirming the inhibitory effect on fat production and cellulite reduction.
상기 과제를 해결하기 위하여, 본 발명은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 항비만용 건강기능식품 조성물을 제공한다. In order to solve the above problems, the present invention provides an anti-obesity health functional food composition containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract as an active ingredient.
또한, 본 발명은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물을 제공한다. In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract, and grape cluster stem extract as an active ingredient.
또한, 본 발명은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 항비만용 사료 첨가제를 제공한다. In addition, the present invention provides an anti-obesity feed additive containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract as an active ingredient.
또한, 본 발명은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 슬리밍(sliming) 화장료 조성물을 제공한다. In addition, the present invention provides a slimming cosmetic composition containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract as an active ingredient.
본 발명은 식물 추출물의 혼합물을 유효성분으로 함유하는 항비만 및 셀룰라이트 감소용 조성물에 관한 것으로, 본 발명의 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 또는 포도송이 줄기 추출물 각각에 비해 지방생성을 억제하고, 중성지방의 함량을 감소시키는 효과가 우수하고, 셀룰라이트 감소효과가 있으므로, 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 본 발명의 조성물은 항비만용 건강기능식품 조성물, 약학 조성물, 사료첨가제 및 슬리밍용 화장료 조성물로 사용할 수 있다. The present invention relates to a composition for reducing anti-obesity and cellulite containing a mixture of plant extracts as an active ingredient, a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract of the present invention Compared to each of extract, celery extract, green tea extract, cedar leaf extract, or grape cluster stem extract, it has excellent effect of suppressing fat production, reducing the content of triglycerides, and has a cellulite reduction effect. The composition of the present invention containing a mixture of green tea extract, green leaf extract and grape cluster stem extract as an active ingredient may be used as a health functional food composition for anti-obesity, pharmaceutical composition, feed additive and cosmetic composition for slimming.
도 1은 지방세포 분화 유도시, 본 발명의 추출물 처리에 의한 지방세포의 분화억제 효과를 Oil Red O 염색을 통해 확인한 결과이다. Normal은 분화 전 지방세포이고, Control은 추출물을 처리하지 않은 분화 유도 지방세포이다.
도 2는 지방세포 분화 유도시, 본 발명의 추출물 처리에 의한 지방세포의 지질형성 억제 효과를 확인한 결과이다. Normal은 분화 전 지방세포이고, Control은 추출물을 처리하지 않은 분화 유도 지방세포이다. ***은 각각의 단독 추출물 처리군에 비해 5종 추출물의 혼합물 처리군의 지질 함량이 유의미하게 감소하였다는 것을 의미하며, p<0.001이다.
도 3은 지방세포 분화 유도시, 본 발명의 추출물 처리에 의한 중성지방 함량의 변화를 확인한 결과이다. Normal은 분화 전 지방세포이고, Control은 추출물을 처리하지 않은 분화 유도 지방세포이다. * 및 **은 각각의 단독 추출물 처리군에 비해 5종 추출물의 혼합물 처리군의 중성지방 함량이 유의미하게 감소하였다는 것을 의미하며, *은 p<0.05, **은 p<0.01이다.
도 4는 본 발명의 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 함유하는 오일 및 크림을 사용한 피시험자의 사용 전, 4주 후 및 8주 후의 디지털 이미지, 표면볼륨 이미지 및 초음파 이미지를 나타낸 결과이다.1 is a result of confirming the effect of inhibiting the differentiation of adipocytes by treatment with the extract of the present invention when inducing differentiation of adipocytes through Oil Red O staining. Normal is adipocytes before differentiation, and Control is differentiation-inducing adipocytes without extract treatment.
2 is a result confirming the effect of inhibiting the lipid formation of adipocytes by the extract treatment of the present invention, when inducing differentiation of adipocytes. Normal is adipocytes before differentiation, and Control is differentiation-inducing adipocytes without extract treatment. *** means that the lipid content of the mixture treatment group of the five extracts was significantly reduced compared to each treatment group alone, p <0.001.
Figure 3 is a result of confirming the change in triglyceride content by the extract treatment of the present invention, when inducing differentiation of adipocytes. Normal is adipocytes before differentiation, and Control is differentiation-inducing adipocytes without extract treatment. * And ** mean that the triglyceride content of the mixture treatment group of the five extracts was significantly reduced compared to each of the individual extract treatment groups, * is p <0.05, ** is p <0.01.
Figure 4 is a digital image of the subject before, after 4 weeks and after 8 weeks using the oil and cream containing a mixture of the bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract of the present invention, This is the result of showing the surface volume image and the ultrasound image.
본 발명은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 항비만용 건강기능식품 조성물에 관한 것이다. The present invention relates to a health functional food composition for anti-obesity containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract as an active ingredient.
본 발명의 일 구현 예에서, 상기 혼합물은 혼합물은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물을 0.5~2:0.5~2:0.5~2:0.5~2:0.5~2 중량비로 혼합할 수 있으며, 바람직하게는 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물을 1:1:1:1:1의 중량비 혼합하는 것이지만, 이에 한정하는 것은 아니다. In one embodiment of the invention, the mixture is a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract 0.5 ~ 2: 0.5 ~ 2: 0.5 ~ 2: 0.5 ~ 2: 0.5 ~ It can be mixed in a weight ratio of 2, preferably a weight ratio of 1: 1: 1: 1: 1, but not limited to, bellflower extract, celery extract, green tea extract, cedar leaf extract, and grape cluster stem extract. .
본 발명의 일 구현 예에서, 상기 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물은 각각 물, C1 내지 C4의 저급 알코올 또는 이들의 혼합물을 용매로 이용하여 추출할 수 있으며, 바람직하게는 도라지 추출물, 셀러리 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물은 에탄올을 용매로 이용하여 추출하고, 녹차 추출물은 물을 용매로 이용하여 추출하는 것이지만, 이에 제한하는 것은 아니다. In one embodiment of the present invention, the bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract are each extracted using water, C 1 to C 4 lower alcohol or a mixture thereof as a solvent. Preferably, the bellflower extract, celery extract, cedar leaf extract, and grape cluster stem extract are extracted using ethanol as a solvent, and the green tea extract is extracted using water as a solvent, but is not limited thereto.
본 발명의 일 구현 예에서, 상기 조성물은 셀룰라이트 감소효과를 나타낸다. In one embodiment of the invention, the composition exhibits a cellulite reduction effect.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 양은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 총 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취인 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is or used with other foods or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient can be appropriately used depending on the purpose of use (prevention or improvement). In general, the health functional food composition of the present invention in the manufacture of a food or beverage is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less with respect to the total raw material. However, in the case of long-term intake for health purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There are no particular restrictions on the type of the health functional food. Examples of foods to which the health functional food composition can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum products, dairy products including ice cream, various soups, beverages, tea Drinks, alcoholic beverages, and vitamin complexes are included, and include all healthy foods in the ordinary sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함할 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the health functional food composition of the present invention may be prepared as a food, particularly a functional food. The functional food of the present invention includes ingredients that are commonly added in food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when prepared as a drink agent, natural carbohydrate or flavoring agent may be included as an additional component in addition to the active ingredient. The natural carbohydrates include monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g. dextrins, cyclodextrins, etc.) or sugar alcohols (e.g. , Xylitol, sorbitol, erythritol, and the like). The flavoring agent may be a natural flavoring agent (eg, tau martin, stevia extract, etc.) and a synthetic flavoring agent (eg, saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.Various nutritional supplements, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonic acid It may further contain a carbonation agent used in the beverage. The proportion of the components to be added is not particularly important, but it is generally selected from the range of 0.01 to 0.1 parts by weight with respect to 100 parts by weight of the health functional food composition of the present invention.
또한, 본 발명은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract, and grape cluster stem extract as an active ingredient.
본 발명의 약학 조성물은 유효성분 이외에 약학적으로 허용되는 담체를 포함할 수 있으며, 이러한 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient, and such a carrier is commonly used in preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, Calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and minerals Oil, and the like, but is not limited thereto. The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc. in addition to the above components.
본 발명에 따른 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. Suitable dosages of the pharmaceutical compositions according to the invention are variously prescribed by factors such as formulation method, mode of administration, patient's age, weight, sex, morbidity, food, time of administration, route of administration, rate of excretion, and response sensitivity. Can be.
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있으며, 비경구 투여의 경우, 정맥 내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and for parenteral administration, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and the like.
본 발명의 약학 조성물은 비만의 억제 및 치료를 위하여 단독으로, 또는 수술, 방사선치료, 호르몬치료, 화학치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다. The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the suppression and treatment of obesity.
본 발명의 조성물에 포함되는 유효성분의 농도는 치료 목적, 환자의 상태, 필요기간 등을 고려하여 결정할 수 있으며 특정 범위의 농도로 한정되지 않는다.The concentration of the active ingredient contained in the composition of the present invention can be determined in consideration of the treatment purpose, the patient's condition, and the required period, and is not limited to a specific range of concentration.
본 발명의 약학 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 주사제, 크림, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제 중에서 선택된 어느 하나의 제형으로 제조될 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention is prepared in a unit dosage form by formulating using a pharmaceutically acceptable carrier or excipient according to a method that can be easily carried out by a person skilled in the art to which the present invention pertains, or It can be prepared by incorporating into a dose container. At this time, the formulation may be prepared as any one of a formulation selected from injections, creams, sprays, ointments, warning agents, lotions, linen agents, pasta agents, and cataplasmas, and may further include a dispersant or a stabilizer.
또한, 본 발명은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 인간을 제외한 동물의 항비만용 사료 첨가제를 제공한다. In addition, the present invention provides an anti-obesity feed additive for animals other than humans that contains a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract, and grape cluster stem extract as an active ingredient.
상기 사료 첨가제는 20~90 중량%의 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 함유하는 고 농축액, 분말 또는 과립형태일 수 있다.The feed additive may be in the form of a high concentrate, powder or granule containing a mixture of 20-90% by weight of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract.
본 발명의 사료 첨가제는 구연산, 후말산, 아디픽산, 젖산, 사과산 등의 유기산이나 인산나트륨, 인산칼륨, 산성피로인산염, 폴리인산염(중합인산염) 등의 인산염이나 폴리페놀, 카테킨(catechin), 알파-토코페롤, 로즈메리 추출물(rosemary extract), 비타민 C, 녹차 추출물, 감초 추출물, 키토산, 탄닌산, 피틴산 등의 천연 항산화제 중에서 선택된 하나 이상을 추가로 포함할 수 있다.The feed additives of the present invention include organic acids such as citric acid, humic acid, adipic acid, lactic acid, and malic acid, or phosphates such as sodium phosphate, potassium phosphate, acidic pyrophosphate, polyphosphate (polymerized phosphate), polyphenols, catechin, alpha -Tocopherol, rosemary extract (rosemary extract), vitamin C, green tea extract, licorice extract, chitosan, tannic acid, may further include one or more selected from natural antioxidants such as phytic acid.
본 발명의 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 함유하는 동물사료 첨가제 및 이를 포함하는 사료는 보조성분으로 아미노산, 무기염류, 비타민, 항생물질, 항균물질, 항산화, 항곰팡이 효소, 소화 및 흡수향상제, 성장촉진제, 질병예방제 등과 같은 물질과 함께 사용될 수 있다.Animal feed additives containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract of the present invention and feed containing them are amino acids, inorganic salts, vitamins, antibiotics, antibacterial substances , Antioxidants, antifungal enzymes, digestive and absorption enhancers, growth promoters, disease preventive agents and the like.
상기 사료 첨가제는 동물에게 단독으로 식용 담체 중에서 다른 사료 첨가제와 조합되어 투여될 수 있다. 또한, 상기 사료첨가제는 탑 드레싱으로서 또는 이들을 동물 사료에 직접 혼합하거나 또는 사료와 별도로, 별도의 경구 제형으로, 주사 또는 경피로 또는 다른 성분과 조합하여 쉽게 투여할 수 있다. 통상적으로, 당 업계에 잘 알려진 바와 같이 단독 일일 투여량 또는 분할 일일 투여량을 사용할 수 있다. 상기 사료 첨가제를 동물 사료와 별도로 투여할 경우, 당 업계에 잘 알려진 바와 같이 추출물의 투여 형태는 이들을 비-독성 제약상 허용 가능한 식용 담체와 조합하여 즉석 방출 또는 서방성 제형으로 제조할 수 있다. 이러한 식용 담체는 고체 또는 액체, 예를 들어 옥수수 전분, 락토스, 수크로스, 콩 플레이크, 땅콩유, 올리브유, 참깨유 및 프로필렌 글리콜일 수 있다. 고체 담체가 사용될 경우, 추출물의 투여형은 정제, 캡슐제, 산제, 토로키제 또는 함당정제 또는 미분산성 형태의 탑 드레싱일 수 있다. 액체 담체가 사용될 경우, 연 젤라틴 캡슐제, 또는 시럽제 또는 액체 현탁액제, 에멀젼제 또는 용액제의 투여 형태일 수 있다. 또한, 투여 형태는 보조제, 예를 들어 보존제, 안정화제, 습윤제 또는 유화제, 용액 촉진제 등을 함유할 수 있다. The feed additive may be administered to animals alone in combination with other feed additives in an edible carrier. In addition, the feed additive can be easily administered as a top dressing or by mixing them directly into animal feed or separately from the feed, in a separate oral dosage form, by injection or transdermal or in combination with other ingredients. Typically, a single daily dose or a divided daily dose can be used, as is well known in the art. When the feed additive is administered separately from the animal feed, the dosage form of the extract, as is well known in the art, can be prepared in an immediate release or sustained release formulation by combining them with a non-toxic pharmaceutically acceptable edible carrier. Such edible carriers can be solid or liquid, such as corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol. When a solid carrier is used, the dosage form of the extract can be a tablet, capsule, powder, torokis or sugar-coated tablets or top dressing in undispersed form. When a liquid carrier is used, it may be in the form of a soft gelatin capsule, or a syrup or liquid suspension, emulsion or solution. In addition, dosage forms may contain adjuvants, such as preservatives, stabilizers, wetting or emulsifying agents, solution accelerators, and the like.
또한, 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물이 사료 첨가제로 포함되는 동물사료는 동물의 식이 요구를 충족시키는데 통상적으로 사용되는 임의의 단백질-함유 유기 곡분일 수 있다. 이러한 단백질-함유 곡분은 통상적으로 옥수수, 콩 곡분 또는 옥수수/콩 곡분 믹스로 주로 구성되어 있다. 상기의 사료 첨가제는 침지, 분무 또는 혼합하여 상기 동물사료에 첨가하여 이용될 수 있다. 본 발명의 수의학적 조성물 또는 사료첨가제는 반려동물의 식이에 적용할 수 있다.In addition, animal feed containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract, and grape cluster stem extract as any feed additive is any protein-containing organic cereal flour commonly used to meet the dietary needs of animals. You can. These protein-containing flours usually consist mainly of corn, soy flour or corn / soy flour mixtures. The feed additive may be used by adding to the animal feed by dipping, spraying or mixing. The veterinary composition or feed additive of the present invention can be applied to the diet of companion animals.
또한, 본 발명은 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 슬리밍(sliming)용 화장료 조성물을 제공한다. In addition, the present invention provides a cosmetic composition for slimming containing a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract as an active ingredient.
본 발명에서 용어, "슬리밍(sliming)"은 체중 감량을 포괄적으로 의미하는 용어로서, 화장품, 마사지 등을 통해 체중이 감소되거나 살이 빠지는 것을 의미한다. 특히, 본 발명에 관한 기술분야에서는, 메이컵에서 피부의 군살을 제거해서 날씬하게 만드는 화장품에 관한 의미로 주로 사용될 수 있다.In the present invention, the term, "sliming (sliming)" is a term that comprehensively refers to weight loss, means that weight loss or weight loss through cosmetics, massage, and the like. In particular, in the technical field of the present invention, it can be mainly used in the sense of cosmetics that make skin slim by removing skin mass from makeup.
상기 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스쳐 로션, 영양로션, 맛사지크림, 영양크림, 모이스처크림, 파운데이션, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저의 제형으로 이루어진 군에서 선택된 어느 하나의 제형을 가지는 것을 특징으로 할 수 있다.The cosmetic composition is a skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, foundation, essence, nutrition essence, pack, soap, cleansing foam, cleansing It may be characterized by having any one formulation selected from the group consisting of lotions, cleansing creams, body lotions and body cleanser formulations.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, and for example, oils, water, surfactants, moisturizers, lower alcohols as common ingredients, Thickeners, chelating agents, pigments, preservatives, fragrances, etc. may be appropriately blended, but are not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures of these can be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, especially in the case of a spray, additional chloro And propellants such as fluorohydrocarbon, propane / butane or dimethyl ether.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, especially in the case of a spray, additional chloro And propellants such as fluorohydrocarbon, propane / butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-Butylglycol oil can be used, in particular cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan. have.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, suspensions such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. can be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.
When the formulation of the present invention is a soap, alkali metal salt of fatty acid, fatty acid hemiester salt, fatty acid protein hydrolyzate, isethionate, lanolin derivative, aliphatic alcohol, vegetable oil, glycerol, sugar, etc. may be used as a carrier component. You can.
이하, 제조예 및 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 제조예 및 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다.
Hereinafter, the present invention will be described in more detail by using manufacturing examples and examples. It is obvious to those skilled in the art that these production examples and examples are only intended to illustrate the present invention more specifically and that the scope of the present invention is not limited by them.
제조예Manufacturing example 1. 추출물의 제조 1. Preparation of Extract
본 발명에서 사용된 도라지(Platycodon grandiflorus) 뿌리는 전라북도 진안군 지역 특산 농산품 매장에서 구입하여 잘게 자른 후 40℃에서 16시간 동안 건조하였다. 건조된 도라지 뿌리(100g)를 분쇄하여 50%(v/v) 에탄올(2,000㎖)에 첨가하여 3일 동안 추출한 후 0.45㎛ 필터를 사용하여 여과하였고, 여과액을 동결건조한 후 회수하여 -20℃에서 보관하면서 실험에 사용하였다. Platycodon used in the present invention The root of the grandiflorus ) was purchased from a specialty agricultural product store in Jinan-gun, Jeollabuk-do, and chopped and dried at 40 ℃ for 16 hours. The dried bellflower root (100 g) was crushed, added to 50% (v / v) ethanol (2,000 mL), extracted for 3 days, filtered using a 0.45 μm filter, and the filtrate was lyophilized and then recovered and recovered at -20 ° C. It was used for the experiment while being stored at.
셀러리(Apium graveolens)는 부산광역시 강서구 봉림동 덕성 셀러리농장에서 건조된 셀러리를 구입하여 셀러리(100g)을 분쇄하여 80%(v/v) 에탄올(2,000㎖)에 첨가하여 3일 동안 추출한 후 0.45㎛ 필터를 사용하여 여과하였고, 여과액을 동결건조한 후 회수하여 -20℃에서 보관하면서 실험에 사용하였다.Celery (Apium graveolens ) purchased dried celery at Deokseong celery farm in Bonglim-dong, Gangseo-gu, Busan, crushed celery (100g), added to 80% (v / v) ethanol (2,000ml), extracted for 3 days, and then used a 0.45㎛ filter. After filtration, the filtrate was lyophilized and collected and used in the experiment while storing at -20 ° C.
녹차 추출 분말(카테킨 함량 38%(w/w) 이상, 물 추출물)은 경기도 포천시 ㈜미래바이오텍에서 구매하여 -20℃에서 보관하면서 실험에 사용하였다.Green tea extract powder (catechin content 38% (w / w) or more, water extract) was purchased from Mirabiotech Co., Ltd., Pocheon-si, Gyeonggi-do, and was used in the experiment while storing at -20 ℃.
고욤나무 잎은 전라북도 진안군 부귀면 수항리 신기마을에서 채취한 후, 우석대학교 한의과대학 방제학 교실의 김홍준 교수에게 의뢰하여 동정하였고, 동정된 표본은 ㈜아토큐앤에이 부설연구소 표본 보관실에 보관하였다. 상기 준비한 고욤잎은 잘게 자른 후 40℃에서 16시간 동안 건조하였다. 건조된 고욤나무 잎(100g)을 분쇄하여 50%(v/v) 에탄올(2,000㎖)에 첨가하고, 3일 동안 추출한 후 0.45㎛ 필터를 사용하여 여과하였고, 여과액을 동결건조한 후 회수하여 -20℃에서 보관하면서 실험에 사용하였다.The leaves of the cedar tree were collected from Singi Village, Suhang-ri, Bugwi-myeon, Jinan-gun, Jeollabuk-do, and then sent to Professor Kim Hong-jun of the Department of Control Science at the Department of Oriental Medicine, Woosuk University, and the identified samples were stored in the specimen storage room of the Atokyu N.A. The prepared goji leaves were chopped and dried at 40 ° C. for 16 hours. The dried redwood leaves (100 g) were crushed and added to 50% (v / v) ethanol (2,000 mL), extracted for 3 days, filtered using a 0.45 μm filter, and the filtrate was lyophilized and recovered − It was used for the experiment with storage at 20 ° C.
머스캣 베일리 A 품종의 포도송이 줄기(stem)는 전북 정읍시 신태인읍 백산리 희망농원에서 구입하여 잘게 자른 후 40℃에서 16시간 동안 건조하였다. 건조된 포도송이 줄기(100g)를 분쇄하여 80%(v/v) 에탄올(2,000㎖)에 첨가하고, 3일 동안 추출한 후 0.45㎛ 필터를 사용하여 여과하였고, 여과액을 동결건조한 후 회수하여 -20℃에서 보관하면서 실험에 사용하였다.The grape cluster stem of Muscat Bailey A was purchased from Hope Farm, Baeksan-ri, Sintaein-eup, Jeongeup-si, Jeollabuk-do, and chopped and dried at 40 ℃ for 16 hours. The dried grape cluster stem (100 g) was crushed and added to 80% (v / v) ethanol (2,000 mL), extracted for 3 days, filtered using a 0.45 μm filter, and the filtrate was lyophilized and recovered − It was used for the experiment with storage at 20 ° C.
도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물은 상기 각각의 추출물을 1:1:1:1:1의 중량비로 혼합하여 제조하였다.
A mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract and grape cluster stem extract was prepared by mixing each extract in a weight ratio of 1: 1: 1: 1: 1.
실시예Example 1. 식물 추출물의 혼합물에 의한 지방세포 분화 억제효과 1. Inhibitory effect of adipocyte differentiation by mixture of plant extracts
상기 제조예 1의 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물, 포도송이 줄기 추출물 또는 이들 5종 추출물의 혼합물에 의한 지방세포 분화 억제효과를 확인하였다.
The effect of inhibiting adipocyte differentiation by the bellflower extract, celery extract, green tea extract, cedar leaf extract, grape cluster stem extract or a mixture of these five extracts of Preparation Example 1 was confirmed.
1) 세포 배양 및 분화1) Cell culture and differentiation
인체지방조직 유래 간엽줄기세포 AD-MSC 세포는 원광대학교병원 인체 유래물 은행에서 구입하였고, 전주대학교 생명윤리위원회의 심의승인서를 획득하여 실험에 사용하였다. AD-MSC 세포를 6-웰 배양용기에 최종농도 5×104 개/㎖가 되도록 분주하고, 성장배지(주식회사 세포바이오, Cat. No. CB-ADMSC-GM, 서울, 한국)에 이틀 동안 배양하였다. 그 후 도라지 추출물(100㎍/ml), 셀러리 추출물(100㎍/ml), 녹차 추출물(100㎍/ml), 고욤나무 잎 추출물(100㎍/ml), 포도송이 줄기 추출물(100㎍/ml) 또는 이들의 혼합물(동일 중량비로 혼합된 총 100㎍/ml)을 지방세포 분화 배지(adipogenic differentiation medium, 주식회사 세포바이오, Cat. No. CB-DM-Adipo, 서울, 한국)에 혼합하여 처리한 후 37℃, 5% CO2 유지되는 배양기에서 14일 동안 배양하였다.
Human adipose tissue-derived mesenchymal stem cells AD-MSC cells were purchased from a human body derivative bank at Wonkwang University Hospital, and obtained a deliberation approval from the Bioethics Committee of Jeonju University and used in the experiment. AD-MSC cells were dispensed into a 6-well culture container to a final concentration of 5 × 10 4 cells / ml, and cultured for 2 days in growth medium (Cell Bio, Cat. No. CB-ADMSC-GM, Seoul, Korea). Did. Then, bellflower extract (100㎍ / ml), celery extract (100㎍ / ml), green tea extract (100㎍ / ml), cedar leaf extract (100㎍ / ml), grape cluster stem extract (100㎍ / ml) Or after mixing and treating the mixture (a total of 100 μg / ml mixed in the same weight ratio) in an adipogenic differentiation medium (Cell Bio, Cat. No. CB-DM-Adipo, Seoul, Korea) The cells were cultured for 14 days in an incubator maintained at 37 ° C and 5% CO 2 .
2) Oil Red O 염색2) Oil Red O dyeing
Oil Red O 염색을 위해 분화된 AD-MSC 세포를 PBS로 세척하고 ㈜세포바이오(서울, 한국)에서 구입한 지방 분화를 위한 염색 키트(Staining kit for adipogenic differentiation kit)를 사용하여 제조사에서 제공한 방법으로 염색하여 현미경으로 관찰하였다(×100, Leika, 베츨라어, 독일). 이후 웰 당 0.5ml의 100% 이소프로필 알코올을 넣어 세포 내 염색물을 용출시켰다. 용출된 염색액은 마이크로플레이트 리더기(Molecular devices, USA)를 이용하여 540nm에서 흡광도를 측정하였다.
Method provided by the manufacturer by washing the differentiated AD-MSC cells with PBS for Oil Red O staining and using the staining kit for adipogenic differentiation kit purchased from Cellbio (Seoul, Korea) It was stained with and observed under a microscope (× 100, Leika, Wetzlar, Germany). Thereafter, 0.5 ml of 100% isopropyl alcohol per well was added to elute intracellular staining. The eluted dye was measured for absorbance at 540 nm using a microplate reader (Molecular devices, USA).
3) AD-MSC 세포에서 중성지방 분석3) Triglyceride analysis in AD-MSC cells
중성지방(triglyceride) 함량 분석은 상업적으로 이용 가능한 분석 키트(Cayman Chemical., 미국)를 제조업자의 프로토콜에 따라 사용하여 측정하였다.
Triglyceride content analysis was determined using a commercially available assay kit (Cayman Chemical., USA) according to the manufacturer's protocol.
4) 결과4) Results
상기 추출물의 제조방법으로 제조된 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물, 포도송이 줄기 추출물 또는 이들 5종 추출물의 혼합물을 지방세포 분화를 유도하는 AD-MSC 세포에 처리하여 14일 동안 배양한 결과, 도 1 및 도 2에 개시된 바와 같이 지방생성이 억제되는 것을 확인하였다. 특히, 지방생성 억제효과는 각각의 추출물을 단독으로 처리한 것에 비해 5종 추출물의 혼합물을 처리하였을 경우 현저하였다. The bellflower extract, celery extract, green tea extract, cedar leaf extract, grape cluster stem extract, or a mixture of these five extracts prepared by the method for preparing the extract is treated with AD-MSC cells inducing adipocyte differentiation for 14 days As a result of culturing, it was confirmed that fat production was inhibited as disclosed in FIGS. 1 and 2. In particular, the effect of inhibiting fat production was remarkable when a mixture of 5 extracts was treated compared to each extract treated alone.
또한. 도 3에 개시된 바와 같이 중성지방의 함량이 개별 추출물 처리군에 비해 5종 추출물의 혼합물 처리군에서 현저히 감소하는 것을 확인하였다. In addition. As shown in Figure 3, it was confirmed that the content of triglycerides was significantly reduced in the mixture treatment group of the five extracts compared to the individual extract treatment group.
실시예Example 2. 식물 추출물의 혼합물에 의한 2. by mixture of plant extracts 셀룰라이트Cellulite 개선 효능 평가 Improvement efficacy evaluation
상기 실시예 1에서 우수한 지방생성 억제효과를 나타낸 도라지 추출물, 셀러리 추출물, 녹차 추출물, 고욤나무 잎 추출물 및 포도송이 줄기 추출물의 혼합물을 이용하여 통상의 방법으로 크림 및 오일을 제조한 후, 상기 크림 및 오일의 셀룰라이트 개선 효능을 평가하였다.
After the cream and oil were prepared in a conventional manner using a mixture of bellflower extract, celery extract, green tea extract, cedar leaf extract, and grape cluster stem extract showing excellent fat generation inhibitory effect in Example 1, the cream and The effectiveness of the cellulite improvement of the oil was evaluated.
1) 시험방법1) Test method
본 시험은 병력 조사 및 피부 상태 진단을 통해 시험 목적에 적합한 여성 피험자 22명을 대상으로 시험참가동의서를 작성하고, 시험에 참여하도록 하였다. 시험제품은 사용법에 따라 사용하도록 하였고, 피험자는 본 연구소를 방문하여 입실하고 20분 동안 항온항습조건(22±2℃, 50±5%)에서 안정을 취한 후 시험에 참여하였다. In this test, 22 women subjects who are suitable for the purpose of the test were prepared through a medical history investigation and skin condition diagnosis. The test product was intended to be used according to the usage, and the subject visited the institute and entered the test after taking stability at constant temperature and humidity conditions (22 ± 2 ℃, 50 ± 5%) for 20 minutes.
평가를 위해, 제품 사용 전과 사용 후 각 시점(4주, 8주 후)에서 대퇴부의 셀룰라이트 사진평가, 피부 거칠기(피부 표면 볼륨), 진피와 피하지방층 경계면 길이, 체질량 지수를 측정하였다.
For evaluation, cellulite photographic evaluation of the femur, skin roughness (skin surface volume), dermal and subcutaneous layer interface length, and body mass index were measured before and after using the product at each time point (4 weeks, 8 weeks later).
2) 오일 및 크림의 사용방법2) How to use oil and cream
본 발명의 오일 및 크림은 8주 동안 1일 2회 아침 및 저녁에 제품을 적당량 취하여 대퇴부에 부드럽게 도포하고, 그 후 중력의 반대방향으로 쓸어 올리듯이 각각 50회 이상 문질러 흡수시키도록 하였다.
The oil and cream of the present invention was taken twice a day in the morning and evening twice a day for 8 weeks, gently applied to the thighs, and then rubbed and absorbed more than 50 times each as sweeping in the opposite direction of gravity.
3) 셀룰라이트 사진평가3) Cellulite photo evaluation
셀룰라이트 사진평가는 제품 사용 전, 사용 4주 및 8주 후 시점에서 디지털 카메라(Nikon D-90, Japan)를 이용하여 촬영한 대퇴부 셀룰라이트 이미지를 회색 등급(gray scale)으로 변환하여 셀룰라이트 상태를 평가하였다. Cellulite photo evaluation is performed by using the digital camera (Nikon D-90, Japan) at the time of product use, 4 weeks, and 8 weeks after use. Was evaluated.
평가는 시험물질 도포 전후의 정보가 없고, 도포 과정과 사진촬영에 관여하지 않은 평가자 2명이 '화장품 표시·광고 실증을 위한 시험방법 가이드 라인'(식품의약품안전평가원, 2014)의 셀룰라이트 판정 등급에 따라 평가하게 하였다.
The evaluation was conducted by two evaluators who had no information before and after the application of the test substance and who were not involved in the application process and photographing, according to the cellulite evaluation grade of the 'Test Method Guidelines for Cosmetic Labeling and Advertising Verification' (Korea Food and Drug Administration, 2014). Were evaluated accordingly.
4) 3차원 이미지 분석 시스템을 이용한 셀룰라이트 부위의 굴곡 측정4) Measurement of the curvature of the cellulite site using a 3D image analysis system
셀룰라이트 부위의 굴곡 측정은 3차원 피부 측정 장치인 PRIMOS® shapescan(GFMesstechnik GmbH, Germany)을 이용하여 측정하였다. 이 기기는 DMD(Digital Micro mirror Devices) 기술을 이용하여 디지털 줄무늬(stripe) 투사를 응용한 비접촉식 기기이다. 각 평가 시점마다 촬영된 영상 이미지는 매칭(matching) 기능을 이용하여 동일한 부위의 측정 및 비교가 가능하다.The measurement of the curvature of the cellulite site was measured using a three-dimensional skin measuring device, PRIMOS® shapescan (GFMesstechnik GmbH, Germany). This device is a contactless device that applies digital stripe projection using DMD (Digital Micro mirror Devices) technology. Video images captured at each evaluation point can be measured and compared in the same area using a matching function.
본 발명에서는 제품 사용 전, 사용 4주 및 8주 후 시점에서 대퇴부를 촬영한 후, 피부 표면의 볼륨(volume of cavities) 파라미터 값을 이용하여 셀룰라이트 부위의 굴곡을 분석하였다.
In the present invention, before the product was used, after 4 weeks and 8 weeks of use, the femoral region was photographed, and the curvature of the cellulite site was analyzed using the volume of cavities parameter value.
5) 초음파를 이용한 셀룰라이트 부위의 진피와 피하지방층 경계면 길이 측정5) Measurement of the length of the interface between the dermis and subcutaneous layer of the cellulite area using ultrasound
진피와 피하지방의 경계면 길이는 Dermascan®C(Cortex, Denmark)를 이용하여 측정하였다. 이 기기는 초음파 진단 영상장치로, 높은 주파수의 음파를 인체 표면에서 보낸 후 인체 내부에서 반사되는 음파를 영상화한다. 밀도가 다른 조직 사이에서 반사된 음파의 개수 및 크기의 합으로 에코의 정도가 결정되고, 이 원리로 인해 셀룰라이트 피부 조직의 수분함량이 색상으로 표현되어 2차원 영상이 촬영된다. 교원질과 수분함량이 풍부한 세포간 기질이 교대로 쌓여있어서 이들 음파저항이 다른 매질사이를 음파가 지나가면 많은 에코가 발생한다. The length of the interface between the dermis and subcutaneous fat was measured using Dermascan®C (Cortex, Denmark). This device is an ultrasound diagnostic imaging device that sends high-frequency sound waves from the surface of the human body and then images the sound waves reflected inside the body. The degree of echo is determined by the sum of the number and size of sound waves reflected between tissues of different densities. Due to this principle, the moisture content of the cellulite skin tissue is expressed in color to capture a two-dimensional image. Since the intercellular matrix rich in collagen and water content is alternately stacked, many echoes are generated when sound waves pass between different mediums with different sound resistance.
본 발명에서는 제품 사용 전, 사용 4주 및 8주 후 시점에서 대퇴부를 측정한 후 B-스캔 모드를 이용하여 진피와 피하지방층 경계면 길이를 분석하였다.
In the present invention, the femoral region was measured at the point of use before and after 4 weeks and 8 weeks of use, and then the length of the interface between the dermis and subcutaneous layer was analyzed using a B-scan mode.
6) 통계분석6) Statistical analysis
데이터의 통계적 유의성은 SPSS® Package Program (IBM, USA)을 이용하여 분석하였다. 사진평가의 경우 시험자간 ICC(Intraclass correlation coefficient) 값이 0.8 이상이면 시험자간의 신뢰도를 인정하여 평균값을 적용하여 분석하였다.Statistical significance of the data was analyzed using SPSS® Package Program (IBM, USA). In the case of photo evaluation, if the intraclass correlation coefficient (ICC) value between testers was 0.8 or higher, the reliability between testers was recognized and analyzed by applying the average value.
정규성은 Shapiro-Wilks test 및 첨도(kurtosis)와 왜도(skewness)를 통해 검증하였다. 시점별 전후 비교는 모수일 경우 동일 피험자에게서 반복 측정한 데이터에 존재하는 상호의존성(교호작용)을 고려하기 위해 반복측정 분산분석법(Repeated Measures ANOVA)을 이용하였다. 통계학적 유의수준은 p 값이 0.05 미만으로 설정하였으며, 증감률은 아래의 식에 따라 계산하였다.Normality was verified by Shapiro-Wilks test and kurtosis and skewness. In the case of comparison between time points, the repeated measures ANOVA was used to take into account the interdependence (interaction) present in the data repeatedly measured from the same subject when the parameters were the same. The statistical significance level was set to p value less than 0.05, and the increase and decrease rate was calculated according to the following equation.
[식 1][Equation 1]
증감율(%)=[(제품 사용 전 측정값-제품 사용 후 측정값)/(제품 사용 전 측정값)]×100
Increase / Decrease (%) = [(Measurement value before using the product-Measured value after using the product) / (Measurement value before using the product)] × 100
7) 결과7) Results
셀룰라이트 사진평가 분석 결과, 본 발명의 5종 추출물의 혼합물을 함유하는 크림 및 오일 사용 전과 비교시, 사용 4주 및 8주 후 시점에서 셀룰라이트 등급이 유의하게 감소하였으며(p<0.05), 감소율은 각각 7.00% 및 13.99%였다. As a result of cellulite photo evaluation analysis, the cellulite grade was significantly reduced ( p <0.05) at 4 and 8 weeks after use, compared to before and after the cream and oil containing the mixture of the five extracts of the present invention were used. Were 7.00% and 13.99%, respectively.
또한, 3차원 이미지 분석 시스템을 이용하여 셀룰라이트 부위의 굴곡을 분석한 결과, 본 발명의 5종 추출물의 혼합물을 함유하는 크림 및 오일 사용 전과 비교시, 사용 4주 및 8주 후 시점에서 피부 표면 볼륨이 유의하게 감소하였으며(p<0.05), 감소율은 각각 6.40% 및 10.01%였다. In addition, as a result of analyzing the curvature of the cellulite site using a three-dimensional image analysis system, as compared with before using cream and oil containing the mixture of the five extracts of the present invention, the surface of the skin at 4 and 8 weeks after use The volume was significantly reduced ( p <0.05), and the reduction rates were 6.40% and 10.01%, respectively.
또한, 초음파를 이용한 셀룰라이트 부위의 진피와 피하지방층 경계면 길이 측정결과, 본 발명의 5종 추출물의 혼합물을 함유하는 크림 및 오일 사용 전과 비교시, 사용 4주 및 8주 후 시점에서 셀룰라이트 부위의 진피와 피하지방층 경계면의 길이가 유의하게 감소하였으며(p<0.05), 감소율은 각각 11.38% 및 17.45%였다. In addition, as a result of measuring the length of the interface between the dermis and subcutaneous substratum layer of the cellulite region using ultrasound, the cellulite region was observed at 4 and 8 weeks after use, compared with before using cream and oil containing the mixture of the five extracts of the invention. The length of the interface between the dermis and subcutaneous layer was significantly reduced ( p <0.05), and the reduction rates were 11.38% and 17.45%, respectively.
도 4는 피시험자 중 1명의 사용 전, 4주 후 및 8주 후의 디지털 이미지, 표면볼륨 이미지 및 초음파 이미지 결과를 나타낸 것으로, 본 발명의 5종 추출물의 혼합물을 함유하는 크림 및 오일 사용 전과 비교하여 사용 시간이 경과함에 따라 셀룰라이트가 감소되어, 표면의 울퉁불퉁함이 개선되고, 진피와 피하지방층 경계면 길이가 감소하는 것을 확인하였다.Figure 4 shows the results of digital images, surface volume images, and ultrasound images before, 4 and 8 weeks after use of one of the subjects, compared to before using creams and oils containing the mixture of the five extracts of the present invention. It was confirmed that cellulite decreases with use time, the surface roughness is improved, and the length of the interface between the dermis and the subcutaneous layer decreases.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180124870A KR102118866B1 (en) | 2018-10-19 | 2018-10-19 | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180124870A KR102118866B1 (en) | 2018-10-19 | 2018-10-19 | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200044307A true KR20200044307A (en) | 2020-04-29 |
| KR102118866B1 KR102118866B1 (en) | 2020-06-05 |
Family
ID=70466605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180124870A KR102118866B1 (en) | 2018-10-19 | 2018-10-19 | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102118866B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102624448B1 (en) * | 2023-01-05 | 2024-01-12 | 조문창 | Method for producing functional fermented ginseng seed extract using grain mushroom mycelium seed culture |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102214624B1 (en) | 2020-09-25 | 2021-02-15 | 허가영 | Anti-obesity composition |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040095949A (en) * | 2003-04-29 | 2004-11-16 | (주)바이오뉴트리젠 | Composition comprising herb with usage to prevent obeseness |
| KR20060094228A (en) * | 2005-02-24 | 2006-08-29 | (주)바이오뉴트리젠 | Food for preventing fatness and hyperlipemia |
| KR20120003693A (en) * | 2010-07-05 | 2012-01-11 | 주식회사 엘지생활건강 | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine |
| KR101464337B1 (en) * | 2013-05-30 | 2014-11-25 | 주식회사 아토큐앤에이 | Composition for anti-obesity comprising extract of Diospyros lotus as effective component |
-
2018
- 2018-10-19 KR KR1020180124870A patent/KR102118866B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040095949A (en) * | 2003-04-29 | 2004-11-16 | (주)바이오뉴트리젠 | Composition comprising herb with usage to prevent obeseness |
| KR20060094228A (en) * | 2005-02-24 | 2006-08-29 | (주)바이오뉴트리젠 | Food for preventing fatness and hyperlipemia |
| KR20120003693A (en) * | 2010-07-05 | 2012-01-11 | 주식회사 엘지생활건강 | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine |
| KR101464337B1 (en) * | 2013-05-30 | 2014-11-25 | 주식회사 아토큐앤에이 | Composition for anti-obesity comprising extract of Diospyros lotus as effective component |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102624448B1 (en) * | 2023-01-05 | 2024-01-12 | 조문창 | Method for producing functional fermented ginseng seed extract using grain mushroom mycelium seed culture |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102118866B1 (en) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5654731B2 (en) | Cyanobacteria extract powder, method for producing the same, and use of Cyanobacteria extract powder | |
| JP5996156B2 (en) | Gene expression promoter for skin beautification, moisturizing composition and skin beautifying composition using the same | |
| JP5479891B2 (en) | Novel royal jelly fraction, its production method and use | |
| US10137070B2 (en) | Composition including ionone or salt thereof as active ingredient and having effect of enhancing skin moisturizing, exfoliating skin, improving skin elasticity, inhibiting erythema, improving skin wrinkles, or alleviating skin photoaging | |
| KR20190112117A (en) | Skin pigmentation inhibitors | |
| CN111053716A (en) | Application of Fuzhuan tea extract in preparation of skin conditioning product | |
| CN101925359A (en) | Composition | |
| CN110278706B (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with strain of Aspergillus coronarius | |
| JP2009256309A (en) | Fat-metabolism improving gene manifestation accelerant and diabetes prevention-related gene manifestation accelerant | |
| KR100902326B1 (en) | Copmosition comprising extract of germinated soybean | |
| TW201225989A (en) | Sugar-free pineapple extract, production method thereof, and application thereof | |
| KR101295368B1 (en) | Composition for skin wrinkle improvement comprising extracts of honeybush extract or its fermentation solution as an active ingredient | |
| KR102118866B1 (en) | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component | |
| KR101796866B1 (en) | Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising at least one selected from the group consisting of cymene, behenic acid, 2-methoxynaphthalene, thymol and salts thereof | |
| JP2010024222A (en) | Collagen production promoter, hyaluronic acid production promoter, and collagen production and hyaluronic acid production promoter | |
| CN106852725A (en) | Composition for improving skin | |
| JP6909569B2 (en) | Skin quality improver | |
| TWI566772B (en) | Whitening agent and malanin production inhibitor | |
| JP2010037221A (en) | Adiponectin production enhancer | |
| JP2011126814A (en) | Collagen production promoter, hyaluronic acid production promoter, and collagen production and hyaluronic acid production promoter | |
| KR101701502B1 (en) | Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising decanal or salt thereof | |
| KR101789518B1 (en) | Composition for improving skin aging and wrinkle comprising Scutellaria baicalensis and Raphanus sativus mixed extract as effective component | |
| JP6933781B2 (en) | AMPK activator | |
| KR102408169B1 (en) | Composition for anti-aging or skin regeneration containing okanin | |
| KR20170138754A (en) | Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising cadaverin or salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right |